PCM
XLRN

Penserra Capital Management’s Acceleron Pharma XLRN Stock Holding History

Penserra Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-512
Closed -$57K – 1157
2020
Q3 		$57K Buy
+512
New +$51K ﹤0.01% 615

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Penserra Capital Management's XLRN Position: Q4 2020 in Review

Penserra Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2020, closing a stake of 512 shares — an estimated $57K sold.

Penserra Capital Management first reported a position in XLRN in Q3 2020 and held it in 1 quarter. The position peaked at $57K in Q3 2020. 253 funds tracked by Wall St. Rank hold XLRN as of Q4 2020.

  • Penserra Capital Management reported no remaining Acceleron Pharma position as of Q4 2020 after selling out during the quarter.
  • Penserra Capital Management sold 512 Acceleron Pharma shares in Q4 2020, an estimated $57K.
  • Penserra Capital Management first reported a position in Acceleron Pharma in Q3 2020 and held it in 1 quarter.
  • Penserra Capital Management's Acceleron Pharma position peaked at $57K in Q3 2020.
  • 253 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2020.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.